Bioluminescent imaging is helping researchers better understand the effectiveness of tissue regeneration enhancers delivered to injured heart tissue by different adeno-associated virus vectors.

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

The Hopewell site is equipped to support clinical-stage development, process-development, and scaleup for cell and gene therapy programs.

JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV ...

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants ...

In the July 2 release, 4DMT explained that the 25% layoffs are part of a move to “streamline operations to offset additional ...

ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today ...

JCR Pharma signs agreement with Alexion for proprietary JUST-AAV capsids to develop genomic medicines: Hyogo, Japan Thursday, July 10, 2025, 10:00 Hrs [IST] JCR Pharmaceuticals Co ...

Snyder, R.O. et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum. Gene Ther. 8, 1891–1900 (1997).

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...